Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials

References

• Booth CM, Eisenhauer EA. Progression-free survival: Meaningful or simply measurable? J Clin Oncol 2012;30:1030–3.
   PubMed Web of Science ®Google Scholar
• Piedbois P, Miller Croswell J. Surrogate endpoints for overall survival in advanced colorectal cancer: A clinician's perspective. Stat Methods Med Res 2008;17:519–27.
   PubMed Web of Science ®Google Scholar
• Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: Insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7–12.
   PubMed Web of Science ®Google Scholar
• Shi Q, De Gramont A, Buyse ME, Grothey A, Schmoll H-J, Seymour MT, et al. Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. ASCO Meeting Abstracts. 2013;31 (15 Suppl):3533.
   Google Scholar
• Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta- analyses of randomized experiments. Biostatistics 2000;1: 49–67.
   PubMedGoogle Scholar
• Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: Often used, sometimes loosely defined. Ann Oncol 2009;20:460–4.
   PubMed Web of Science ®Google Scholar
• Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, et al. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: Literature-based analysis from 50 randomized first-line trials. Clin Cancer Res 2013;19: 225–35.
   PubMed Web of Science ®Google Scholar
• Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25:4562–8.
   PubMed Web of Science ®Google Scholar
• Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, et al. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. Int J Colorectal Dis 2012;27:623–34.
   PubMed Web of Science ®Google Scholar
• Sidhu R, Rong A, Dahlberg S. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clin Cancer Res 2013;19:969–76.
   PubMed Web of Science ®Google Scholar
• Saad ED, Buyse M. Overall survival: Patient outcome, therapeutic objective, clinical trial end point, or public health measure?J Clin Oncol 2012;30:1750–4.
   PubMed Web of Science ®Google Scholar
• Arnold D, Stein A. New developments in the second-line treatment of metastatic colorectal cancer: Potential place in therapy. Drugs 2013;73:883–91.
   PubMed Web of Science ®Google Scholar
• Guglielmi AP, Sobrero AF. Second-line therapy for advanced colorectal cancer. Gastrointest Cancer Res 2007;1:57–63.
   PubMedGoogle Scholar
• Roque IFM, Sola I, Martin-Richard M, Lopez JJ, Bonfill Cosp X. Second-line chemotherapy in advanced and metastatic CRC. Cochrane Database Syst Rev2009(2):CD006875.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Saad ED, Katz A, Buyse M. Overall survival and post- progression survival in advanced breast cancer: A review of recent randomized clinical trials. J Clin Oncol 2010;28: 1958–62.
   PubMed Web of Science ®Google Scholar
• Burzykowski T, Molenberghs G, Buyse M. The evaluation of surrogate endpoints. New York, NY: Springer; 2005.
   Google Scholar
• Piedbois P, Buyse M. Meta-analyses based on abstracted data: A step in the right direction, but only a first step. J Clin Oncol 2004;22:3839–41.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013;14:29–37.
   PubMed Web of Science ®Google Scholar
• Cohn AL, Hecht JR, Dakhil S, Saleh MN, Piperdi B, Cline-Burkhardt VJM, et al. SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2013;31(15 Suppl):3616.
   Google Scholar
• Eng C, Hart LL, Severtsev A, Gladkov O, Mueller L, Kopp MV, et al. A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. ASCO Meeting Abstracts. 2013;31(15 Suppl):3508.
   Google Scholar
• Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–13.
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311–9.
   PubMed Web of Science ®Google Scholar
• Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 2013;31:2110–4.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). ASCO Meeting Abstracts. 2013;31(18 Suppl):LBA3506.
   Google Scholar
• Sommeijer DW, Shi Q, Meyers JP, Sjoquist KM, Hoff PM, Seymour MT, et al. Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. ASCO Meeting Abstracts. 2013;31(15 Suppl):3520.
   Google Scholar
• Bendell JC, Tournigand C, Bednarczyk M, Swieboda-Sadlej A, Chung I, Barone C, et al. Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts. 2011;29(4 Suppl):478.
   Google Scholar
• Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol 2013;24:1777–85.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807–14.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539–44.
   PubMed Web of Science ®Google Scholar
• Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH, Jr., Bodoky G, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008;26:4544–50.
   PubMed Web of Science ®Google Scholar
• Hoehler T, Decker T, Schimanski C, Schmitz SH, Kanzler S, Rauh J, et al. Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment. ASCO Meeting Abstracts. 2013;31(15 Suppl):3586.
   Google Scholar
• Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Jr., Philip PA, Mitchell E, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009;27:2848–54.
   PubMed Web of Science ®Google Scholar
• Masi G, Loupakis F, Salvatore L, Cremolini C, Fornaro L, Schirripa M, et al. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III ‘BEBYP’ trial by the Gruppo Oncologico Nord Ovest (GONO). ASCO Meeting Abstracts. 2013; 31(15 Suppl):3615.
   Google Scholar
• Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: A randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853–60.
   PubMed Web of Science ®Google Scholar
• Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013; 108:503–11.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003;21:2059–69.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study. Ann Oncol 2008;19:1720–6.
   PubMed Web of Science ®Google Scholar
• Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, et al. Antitumour activity of three second- line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomised, multicentre phase II study. Ann Oncol 2002;13:1558–67.
   PubMed Web of Science ®Google Scholar
• Schoemaker NE, Kuppens IE, Moiseyenko V, Glimelius B, Kjaer M, Starkhammer H, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 2004;91:1434–41.
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, et al. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer Chemother Pharmacol 2003;52:514–9.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011;29:2004–10.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499–506.
   PubMed Web of Science ®Google Scholar